In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
about
The choreography of HIV-1 proteolytic processing and virion assemblyHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsStructural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistanceKinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirA potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavirIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitorsIn vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesGenetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorImpaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitorsThe Geogenomic Mutational Atlas of Pathogens (GoMAP) web systemAn Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavirSingle-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapyIdentification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesComputational study of protein specificity: the molecular basis of HIV-1 protease drug resistance.Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisComputational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitorsLongitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 proteaseEmergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detectionInterplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivityA Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutantsThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Human Immunodeficiency Virus Gag and protease: partners in resistance.
P2860
Q27009643-40DC0B83-B6A1-480F-99BF-5E12111BB7CFQ27650325-8F591481-C8BD-48AC-BB35-16FABC6FECBFQ27676079-EB4D0107-73E4-475A-A14C-135DD144784BQ27678735-826F2AB1-6F2E-4361-8F13-87C6F92D2024Q28281045-C3485B01-3B86-45F8-9B88-D90CF6FC38CDQ28344112-C048DCE9-FB36-4530-9CED-AAAEF9227B60Q28344457-5ADC0CA4-EA90-44E2-84FD-DCD66C654AA8Q28344511-8231BB32-BEA1-4534-A379-FA3732223EDCQ28344594-1CE0E552-A9ED-4C7C-8BEA-FA88729104F4Q28368369-ED7A0B02-F22B-442B-9443-8D4C9689A3C8Q28369030-594A0409-6F2E-472D-ACD1-323779903C04Q28378860-AC90AAC8-C8C1-46C9-AC64-55ECCD456BB9Q28379223-B7D8B185-4FA4-462B-8600-368A1E999847Q28379356-DF1DC805-CD48-4FA5-A55A-1F41537F8AB6Q28379411-A9591948-AC36-4C9E-97C4-7ADFA4FBDEC6Q28541636-A47DF8AB-EFBB-47B2-98AD-9EB7D63D7297Q31963272-6DC809C3-EB7E-40D4-9791-12EBCDEFF667Q33554955-99883E76-6445-41EF-B9C5-34E9820A93E6Q33784635-BADEB5DA-A419-4445-B82C-B1BADC209AA6Q33804495-F1064A26-C6E2-478B-BB48-9DA093A50AC2Q33906239-04F3B332-6C90-44E6-859D-CA6C15DD7D8BQ33935276-C6F40020-5747-4EF2-BBEA-2F0D659A7AE1Q33952774-5622E463-AE79-4F25-8877-067265B04E7EQ33977160-9697BD12-C264-42B0-AE92-CAB0B343117EQ34005107-7A827F34-AE2F-458E-AA15-0F93B675D400Q34010283-5AA01154-CA29-43E5-ACFA-EC135F1CC009Q34044221-7D283411-5B94-480A-B4AE-B9D9ADD052DAQ34108198-5452136C-2D71-4DC9-84ED-10B8A036384BQ34113737-1CE39293-B735-4177-AC0C-884601719B2AQ34454630-1CDDC914-802C-49F5-93CD-0F2DCD21C415Q34526179-ACEBC92C-29E5-4BC8-8D88-7CAF1A82F456Q35129066-B41E78D4-0466-459D-BD15-56B303667D62Q35689381-AC81F036-9401-4921-8F6A-4055719CC12FQ35742512-8B0D1F7E-14D8-4135-9C9C-45ABFA1A410EQ35857907-DE45911E-0889-436D-B41C-5AA68E4A6E19Q36034959-255C0866-25AF-4C82-97BC-16CC4297BB22Q37018369-47C1F594-5CBC-486E-B01B-D0529060B66BQ37115695-4B617A4A-9203-4748-AD9B-02AFC7D27A2AQ37410823-2BCBE8A4-50FA-4ED1-9C62-67C73F5FA868Q38032330-621960EE-29B4-442F-ACA4-8732B2204BA8
P2860
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@ast
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@en
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@nl
type
label
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@ast
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@en
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@nl
prefLabel
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@ast
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@en
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@nl
P2093
P2860
P1433
P1476
In vitro selection and charact ...... ors of HIV-1 aspartyl protease
@en
P2093
A B Cullinan
B Maschera
C Falcione
J A Partaledis
K Yamaguchi
S Pazhanisamy
P2860
P304
P407
P577
1995-09-01T00:00:00Z